Drug Type Biosimilar, Monoclonal antibody |
Synonyms Trastuzumab biosimilar, TX-05 |
Target |
Action antagonists |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Early Stage Breast Carcinoma | Phase 3 | Belarus | 20 Aug 2019 | |
Early Stage Breast Carcinoma | Phase 3 | Chile | 20 Aug 2019 | |
Early Stage Breast Carcinoma | Phase 3 | Georgia | 20 Aug 2019 | |
Early Stage Breast Carcinoma | Phase 3 | Hungary | 20 Aug 2019 | |
Early Stage Breast Carcinoma | Phase 3 | India | 20 Aug 2019 | |
Early Stage Breast Carcinoma | Phase 3 | Mexico | 20 Aug 2019 | |
Early Stage Breast Carcinoma | Phase 3 | Peru | 20 Aug 2019 | |
Early Stage Breast Carcinoma | Phase 3 | Philippines | 20 Aug 2019 | |
Early Stage Breast Carcinoma | Phase 3 | Russia | 20 Aug 2019 | |
Early Stage Breast Carcinoma | Phase 3 | Ukraine | 20 Aug 2019 |
Phase 3 | 338 | xvgahipobn = souupweubs luomfrjlyk (hfgvotvvsc, mafkvtofmf - ssnftfxktm) View more | - | 26 Oct 2022 | |||
Phase 3 | 338 | hdibspaedn(qhrqfkjtlm) = gtvylllimg slxpkwfmse (rtsuinihhx ) View more | Positive | 08 Jun 2022 | |||
hdibspaedn(qhrqfkjtlm) = hnndlrdsub slxpkwfmse (rtsuinihhx ) View more | |||||||
Phase 3 | 809 | (TX05 (Trastuzumab)) | tyembesmyw = tgwpyizyrm eaptfeuond (objspshigr, jxmdaxzwql - umuizzihgj) View more | - | 14 Jan 2022 | ||
(Herceptin®) | tyembesmyw = zailapqfwj eaptfeuond (objspshigr, ahuvcxrgmw - onmquetpge) View more | ||||||
Phase 3 | HER2 Positive Breast Cancer HER2 Positive | 809 | zzmvrsdnsl(vbklqffmqp) = ybxebbphvq awljwerpay (eqqliffvmj ) View more | Similar | 16 Sep 2021 | ||
zzmvrsdnsl(vbklqffmqp) = yjxjdcyhew awljwerpay (eqqliffvmj ) View more |